Skip to main content
Equibles

K2 PRINCIPAL FUND, L.P.

Position in QURE — uniQure N.V.

CIK 1461790 TORONTO, A6
Back to QURE Full portfolio

Position in QURE

as of Jun 30, 2026 · filed Aug 7, 2026
Position Value
$3,620,362
+$1,681,252 QoQ
Shares Held
78,601
-33.7% QoQ
Ownership
0.125%
of shares outstanding
% of Portfolio
0.96%
of 13F equity value
Holder Rank
#88
of 254 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in QURE Over Time

Shares Held

Position Value (USD)

Derivatives in QURE

reported options exposure · as of Jun 30, 2026
CallValue
$2,303,000
CallShares
50,000
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

K2 PRINCIPAL FUND, L.P. holds $13,545,573 across 5 Biotechnology names. QURE ranks #1 (26.7% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 QURE
uniQure N.V.
This page 		78,601 $3,620,362
2 NKTR
Nektar Therapeutics
 50,465 $3,522,961
3 ABVX
Abivax S.A.
 24,403 $3,251,943
4 SPRY
ARS Pharmaceuticals, Inc.
 375,132 $3,004,807
5 TENX
Tenax Therapeutics, Inc.
 10,000 $145,500

All Filings in QURE

Export CSV
4 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $2,303,000 50,000
2026-06-30 $3,620,362 78,601
2026-03-31 $2,370,750 145,000
2026-03-31 $1,939,110 118,600